Mr. Speaker, I can assure the member and Canadians that we are up to speed. We encourage manufacturers to submit pediatric information and to introduce an additional six-month data protection for drugs if they are filed for pediatric indication. In addition, our government created an independent pediatric expert advisory committee to provide advice on the development, licensing and vigilance of products.
In the House of Commons on June 15th, 2011. See this statement in context.